Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis.
Roland Klingenberg,Norbert Gerdes,Robert M. Badeau,Anton Gisterå,Daniela Strodthoff,Daniel F. J. Ketelhuth,Anna M. Lundberg,Mats Rudling,Stefan K. Nilsson,Gunilla Olivecrona,Stefan Zoller,Christine Lohmann,Thomas F. Lüscher,Matti Jauhiainen,Tim Sparwasser,Göran K. Hansson +15 more
Reads0
Chats0
TLDR
In this article, the authors support the use of regulatory T cells (Tregs) as inhibitors of atherosclerosis, however, the mechanistic properties of Tregs are unknown.Abstract:
Atherosclerosis is a chronic inflammatory disease promoted by hyperlipidemia. Several studies support FOXP3-positive regulatory T cells (Tregs) as inhibitors of atherosclerosis; however, the mechan ...read more
Citations
More filters
Journal ArticleDOI
Immunity and Inflammation in Atherosclerosis.
Dennis Wolf,Klaus Ley,Klaus Ley +2 more
TL;DR: The pathogenesis of atherosclerosis is discussed with a focus on adaptive immunity and some limitations of animal models and the need for models that are tailored to better translate to human Atherosclerosis and ultimately progress in prevention and treatment are discussed.
Journal ArticleDOI
The immunology of atherosclerosis
Anton Gisterå,Göran K. Hansson +1 more
TL;DR: A need exists for novel therapies to stabilize plaques and to treat arterial inflammation, and patients with CKD would likely benefit from such preventive measures.
Journal ArticleDOI
Inflammation and plaque vulnerability
TL;DR: The molecular mechanisms involved in plaque vulnerability and the development of atherothrombosis are discussed and plaques with reduced collagen content are thought to be more vulnerable than those with a thick collagen cap.
Journal ArticleDOI
Immune effector mechanisms implicated in atherosclerosis: from mice to humans.
TL;DR: Current experimental and clinical knowledge of the pathogenesis of atherosclerosis is reviewed through an immunological lens and how host defense mechanisms essential for survival of the species actually contribute to this chronic disease but also present new opportunities for its mitigation.
Journal ArticleDOI
Animal Models of Atherosclerosis
TL;DR: The use of mouse models with the ability to turn on or delete proteins or cells in tissue specific and temporal manner will be very valuable as it becomes clear that different factors may influence different stages of lesion development.
References
More filters
Journal ArticleDOI
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Glynn Dennis,Brad T. Sherman,Douglas A. Hosack,Jun Jun Yang,Wei Gao,H. Clifford Lane,Richard A. Lempicki +6 more
TL;DR: DAMID is a web-accessible program that integrates functional genomic annotations with intuitive graphical summaries that assists in the interpretation of genome-scale datasets by facilitating the transition from data collection to biological meaning.
Journal ArticleDOI
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
TL;DR: Foxp3, which encodes a transcription factor that is genetically defective in an autoimmune and inflammatory syndrome in humans and mice, is specifically expressed in naturally arising CD4+ regulatory T cells and retroviral gene transfer of Foxp3 converts naïve T cells toward a regulatory T cell phenotype similar to that of naturally occurring CD4+.
Journal ArticleDOI
Inflammation, Atherosclerosis, and Coronary Artery Disease
TL;DR: The evidence is recounted that atherosclerosis, the main cause of CAD, is an inflammatory disease in which immune mechanisms interact with metabolic risk factors to initiate, propagate, and activate lesions in the arterial tree.
Journal ArticleDOI
Foxp3 programs the development and function of CD4 + CD25 + regulatory T cells
TL;DR: It is reported that the forkhead transcription factor Foxp3 is specifically expressed in CD4+CD25+ regulatory T cells and is required for their development and function and ectopic expression ofFoxp3 confers suppressor function on peripheral CD4-CD25− T cells.
Journal ArticleDOI
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Colin Baigent,Anthony C Keech,Patricia M. Kearney,L Blackwell,Georgina Buck,Christine Pollicino,Adrienne Kirby,T Sourjina,Richard Peto,Rory Collins,R. J. Simes +10 more
TL;DR: Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics.